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In ThIs Issue
•	 Total Lesion Glycolysis 
in Positron emission 
Tomography Can Predict 
Gefitinib Outcomes in 
non–small-Cell Lung 
Cancer with Activating 
EGFR Mutation
This study investigated the predictive value of quantitative 
metabolic parameters using total lesion glycolysis (TLG) 
measured by 18F-2-fluoro-2-deoxyglucose-positron 
emission tomography/computed tomography (FDG-
PET/CT) in outcome from first-line gefitinib therapy for 
patients with epidermal growth factor receptor (EGFR)-
mutant non–small-cell lung cancer (NSCLC). Wholebody 
FDG-PET/CT scans were performed in a total of 75 
patients prior to first-line gefitinib. These patients 
achieved an overall response rate (ORR) of 69.4%, and 
median progression-free survival (PFS) of 11.5 months. 
When stratified by TLG levels (low, intermediate, and 
high), no significant difference in ORR was observed 
(68.0%, 76.0% and 68.0%, respectively; p = 0.274) 
whereas PFS was significantly different by TLG levels, 
with high TLG associated with shorter PFS (24.2 months, 
11.9 months and 7.2 months, respectively; p < 0.001). 
There was also a significant association between TLG 
and overall survival (p = 0.005). Multivariate analysis 
adjusted for disease status and response to gefitinib 
demonstrated that TLG was an independent predictive 
factor for PFS. Taken together, the data indicate that 
TLG is of predictive value for PFS and development of 
resistance to gefitinib in the study population. Time to 
acquired resistance could be predicted with the use of 
baseline metabolic tumor burden measured by TLG prior 
to first-line gefitinib. (p. 1189)
•	 Patterns of Disease 
Recurrence after sABR for 
early stage non–small-Cell 
Lung Cancer: Optimizing 
Follow-Up Schedules for 
Salvage Therapy
The authors described incidence and salvage of local 
recurrences (LR) and second primary lung cancers 
(SPLC) after stereotactic ablative radiotherapy (SABR) 
in 855 patients with long-term follow-up (median 52 
months). Patients with double tumors, TNM-stages other 
than T1-T2N0M0, biologically effective dose less than 
100 Gy
10
 and prior treatment were excluded from the 
analysis. LR was found in 46 patients after a median of 
22 months. Isolated LR was observed in 54% of patients 
and LR combined with regional recurrences was found in 
13%. Three- and 5-year actuarial local control rates were 
92.4% and 90.9%, respectively. Radical salvage treatment 
was performed in 10 patients: surgery in 6, high-dose 
radiotherapy in 3, and chemoradiation in 1. Patients 
achieved a median overall survival of 13 months after 
LR, and 36 months after radical salvage. After a median 
interval of 34 months, 79 patients had SPLC, with 3- and 
5-year actuarial cumulative incidences of 11.7% and 
16.7%, respectively. Sixty three patients (80%) underwent 
radical salvage for SPLC. The findings support long-term 
follow-up using computed tomography scans for patients 
receiving radical treatment. (p. 1195)
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ReseARCh WATCh
•	 Rociletinib in EGFR-
Mutated non–small-Cell 
Lung Cancer
The phase I/II study assessed the safety, preliminary 
antitumor activity and pharmacokinetics of the EGFR 
inhibitor rociletinib in 130 patients with EGFR-mutated 
NSCLC, who progressed on EGFR inhibitor therapy. 
Free-base form of rociletinib (150 mg once daily to 
900 mg twice daily) was given to the first 57 patients 
enrolled while the hydrogen bromide salt (HBr) form 
(500 mg twice daily to 1000 mg twice daily) was given 
to the remaining patients. The expansion cohorts 
received rociletinib at 500 mg twice daily, 625 mg 
twice daily, or 750 mg twice daily. The maximum 
tolerated dose was not determined. Hyperglycemia 
was the only common dose-limiting adverse event. 
The objective response rate and disease control rate in 
46 evaluable T790M-positive patients were 59% and 
93%, respectively, and 29% and 59%, respectively, in 
17 evaluable T790M-negative patients. The findings 
indicate tumor responses and sustained disease control 
from rociletinib treatment in EGFR-mutated NSCLC 
patients with T790M resistance mutation. Larger studies 
are ongoing to confirm the results.
Sequist LV, Soria J-C, Goldman JW, et al. Rociletinib 
in EGFR-mutated non–small-cell lung cancer. NEJM 
2015;372:1700–1709.
This study assessed gene fusions and nucleotide variants 
using deep targeted next-generation sequencing in 
72 lung mucinous adenocarcinomas from the US and 
Korea, and correlated the profile with survival and other 
clinical parameters. The most frequent driver mutation 
in this mucinous cohort was KRAS mutations (63%), 
with a distribution of nucleotide position alteration, 
G12D and G12V, more similar to that in gastrointestinal 
tumor versus other lung tumors. A number of gene 
fusions (CD74-NRG1, VAMP2-NRG1, TRIM4-BRAF, 
TPM3-NTRK1, and EML4-ALK) and mutations 
(ERBB2, BRAF, and PIK3CA) were found in KRAS-
negative cases while TP53 mutation was rare (n=2). 
The overall mutation burden was low, independent of 
smoking status, and could be associated with TP53 
status. Recurrence-free survival was similar to stage-
matched non-mucinous tumors, with all recurrence 
sites limited to the lungs without extra-pulmonary 
metastases, suggesting a non-aggressive phenotype of 
mucinous adenocarcinomas. The findings demonstrated 
that invasive mucinous adenocarcinoma of the lung is 
genetically and clinically distinct. The authors suggested 
that the disease could potentially show durable response 
to targeted therapies as a result of the limited number of 
driver mutations associated with it. (p. 1156)
•	 unique Genetic and 
survival Characteristics 
of Invasive Mucinous 
Adenocarcinoma of the 
Lung
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In this phase I trial, nivolumab (1, 3, or 10 mg/kg once 
every 2 weeks) was evaluated in 129 patients with 
heavily pretreated advanced non-small cell lung cancer 
(NSCLC). Patients achieved a median overall survival 
(OS) of 9.9 months across doses, with OS rates of 42% 
(1-year), 24% (2-year) and 18% (3-year). The 3-mg/
kg dose, chosen for further clinical development, 
achieved 1-, 2-, and 3-year OS rates of 56%, 42%, and 
27%, respectively. Objective responses were observed 
in 22 patients (17%), with median response duration 
of 17.0 months, while unconventional immune-pattern 
responses were observed in 6 patients (5%). Treatment 
termination occurred in 18 responding patients, half of 
which had >9 months lasting response following the last 
dose. Drug-related adverse events of grade 3 to 4 were 
observed in 14% of patients, and drug-related deaths 
occurred in 2%. The data suggest durable responses and 
good survival rates in the study population treated with 
nivolumab monotherapy, which should be confirmed in 
ongoing randomized studies.
Gettinger SN, Horn L, Gandhi L, et al. Overall 
survival and long-term safety of nivolumab (anti-
programmed death 1 antibody, BMS-936558, ONO-
4538) in patients with previously treated advanced 
non-small-cell lung cancer. J Clin Oncol, doi:10.1200/
jco.2014.58.3708 (2015).
•	 Genomic Characterization 
of non–small-Cell 
Lung Cancer in African 
Americans by Targeted 
Massively Parallel 
sequencing
The authors conducted in-depth evaluation of molecular 
profile of non-small cell lung cancer (NSCLC) in 99 
African American patients, an ethnic group with increased 
lung cancer incidence and mortality rates but have been 
underrepresented in genetic analysis of the disease. 
The cohort consisted of 61% males, 94% smokers, and 
31 squamous and 68 nonsquamous cell carcinomas. 
The results of sequencing the coding regions of 81 
NSCLC-related genes and 40 ancestry-informative 
markers revealed 227 nonsilent variants in the coding 
sequence, including 24 cases of nonoverlapping classic 
driver mutations. There was no significant difference in 
driver mutation incidence between the cohort and the 
whites. Generic ancestry was not associated with the 
presence of somatic mutations. Squamous cell carcinomas 
demonstrated amplifications in the 3q chromosome arm, 
suggesting targetable alterations. Driver-negative tumors 
showed frequent SMARCA4 mutations and protein loss. 
The findings suggest that the incidence of somatic driver 
mutations in NSCLC might not be significantly different 
between individuals of African American ancestry and 
those of European ancestry.
Araujo LH, Timmers C, Bell EH, et al. Genomic 
characterization of non-small-cell lung cancer in African 
Americans by targeted massively parallel sequencing. 
J Clin Oncol, doi:10.1200/jco.2014.59.2444 (2015).
•	 Overall survival and Long-
Term safety of nivolumab 
(Anti–Programmed Death 
1 Antibody, BMs-936558, 
OnO-4538) in Patients 
With Previously Treated 
Advanced non–small-Cell 
Lung Cancer
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Schumer and colleagues reported that the use of breath 
analysis for exhaled carbonyl compounds in lung cancer 
screening is comparable to the findings of the National 
Lung Screening Trial (NLST). The retrospective study 
involved patients with lung cancer (n = 162), benign 
disease (n = 86), and controls (n = 187), with similar 
stage and histology distribution to that of the NSLT. One 
liter of breath was collected from a single exhalation, 
from which the exhaled carbonyl compounds were 
analyzed. Positive results were found in >97% of the 
lung cancer group, 82.6% of the benign group, and 
32.6% of the controls. Early-stage cancer was shown 
in 64.6% of the lung cancer patients by the breath test 
versus 57.1% by the NLST study. The breath test has a 
sensitivity of 97.5% for all lung cancer, and 96.1% for 
early-stage disease, with at least one increased carbonyl 
cancer marker. Its specificity is proportional to number 
of increased cancer markers (51.6% with 1 marker to 
94.5% with 3 markers). The investigators concluded that 
the data suggest the potential of breath analysis as the 
initial lung cancer screening modality, which is simple, 
less expensive and lower radiation exposure. Further 
studies are warranted to confirm the findings.
•	 AsCO Annual Meeting 
2015: A phase III study 
(CheckMate 017) of 
nivolumab (nIVO; anti-
programmed death-1  
[PD-1]) vs docetaxel 
(DOC) in previously 
treated advanced or meta-
static squamous (sQ) cell 
non-small cell lung cancer 
(nsCLC) (Abstract 8009)
The CheckMate 017 trial is a randomized, open-
label, global phase III study comparing nivolumab 
with docetaxel in SQ NSCLC patients whose disease 
progressed on platinum-based doublet chemotherapy 
(n = 272). Compared with the docetaxel arm (n = 137), 
the nivolumab arm (n = 135) achieved significantly 
better overall survival (OS; hazard ratio [HR] = 0.59; 
p = 0.00025), progression-free survival (PFS; HR 
= 0.62; p = 0.0004), and objective response rate 
(ORR; 20 vs. 9%; p = 0.0083) independent of PD-L1 
expression. The safety profile of nivolumab was 
favorable versus docetaxel: grade 3–4 drug-related 
adverse events 7% vs. 55%, and 0 vs. 3 deaths. The 
primary objective of CheckMate 017 has been met; 
second-line nivolumab showed superior OS, PFS 
and ORR with a more favorable safety profile versus 
docetacel in previously treated SQ NSCLC. Tumor 
PD-L1 status was not prognostic or predictive for 
treatment outcomes.
neWs In BRIeF
•	 AATs Annual Meeting 
2015: Breath analysis 
for lung cancer screen-
ing comparable to nLsT 
(Abstract: LB3)
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This study compared nivolumab (anti-PD-1 antibody) 
with docetaxel in 582 patients with advanced non-SQ 
NSCLC whose disease progressed after platinum-based 
doublet chemotherapy. Compared to the docetaxel 
group, the nivolumab group achieved superior overall 
survival (12.2 vs. 9.4 months), higher response 
rates (19.2 vs. 12.4%), and significantly longer 
median duration of response (17.1 vs. 5.6 months). 
PD-L1 expression was associated with benefit from 
nivolumab. A 27% lower risk of death was observed 
in the nivolumab group versus the docetaxel group; a 
41–60% reduction in risk of death was observed in the 
subgroup with high levels of PD-L1 (≥1% tumor cells). 
Nivolumab was more favorable than docetaxel: 10.5 
vs. 53.7% serious side effects; 4.9 vs. 14.9% treatment 
discontinuation; 0 vs. 1 treatment-related death. In 
summary, nivolumab demonstrated survival benefit 
with a well-tolerated safety profile in advanced non-SQ 
NSCLC when compared with docetaxel.
neWs FROM The IAsLC 
TOBACCO COnTROL 
COMITTee
•	 e-Cigarettes
cause lung damage. This is particularly interesting given 
the recent CDC findings that e-cigarette use has now 
overtaken that of other tobacco products in American 
middle and high school students. Do e-cigarettes really 
help with tobacco smoking cessation? Not according 
to data presented at the American Thoracic Society 
meeting in Denver, May 2015, reported on Medscape. 
Researchers present findings from a review of 297 
full-text papers with a safety review of 18 papers that 
reported adverse effects of e-cigarettes. They found that 
e-cigarettes may have an effect on number of cigarettes 
smoked and that at 1-month, e-cigarettes had a greater 
effect on cessation than placebo. This effect did not 
persist at 3 and 6 months and the session moderator felt 
unable to endorse e-cigarettes as a smoking cessation 
tool. And lastly, e-cigarettes have come under pressure 
in Wales, where a new public health law put them 
under restrictions including measures to restrict sales to 
under-18s and a ban on e-cigarette use in enclosed public 
spaces, due to take effect in 2017.
http://australianaviation.com.au/2015/06/
casa-bans-e-cigarettes-from-check-in-luggage/
http://www.flightsafetyaustralia.
com/2014/10/e-cigarette-sparks-fiery-debate/
http://www.faa.gov/about/initiatives/hazmat_safety/
more_info/?hazmat=61
http://www.cdc.gov/media/releases/2015/p0416-e-
cigarette-use.html
http://www.ncbi.nlm.nih.gov/pubmed/24999835
http://www.medscape.com/viewarticle/845259
http://www.bbc.com/news/uk-wales-33025872
•	 AsCO Annual Meeting 
2015: Phase III, random-
ized trial (CheckMate 
057) of nivolumab (nIVO) 
versus docetaxel (DOC) in 
advanced non-squamous 
cell (non-sQ) non-small 
cell lung cancer (nsCLC) 
(Abstract LBA109)
Clearly, these devices are not going away anytime soon. Among the 
news on e-cigarettes this months are aviation updates, lung damage 
from vapor and the benefits, or lack in smoking cessation.
The Australian aviation regulator, CASA, has banned e-cigarettes 
from checked luggage. This has to do with the lithium-ion batteries 
that power them, which pose a potential fire risk if activated in a 
confined space such as a baggage compartment. A possible tragedy 
was averted in August 2014 when baggage handlers located a 
smoking bag while loading it onto a flight at Boston-Logan airport. 
Evidently the bag, which was soft-sided, contained an e-cigarette 
which was switched on by pressure from surrounding luggage on 
its “push button”. So e-cigarettes, at least in Australia, are restricted 
to carry-on luggage in the cabin, where of course they cannot be 
used. At the moment the American aviation regulator, the FAA, 
just recommends that e-cigarettes are carried in the cabin only with 
reference to individual airline policy. A report from the American 
Journal of Physiology (see abstract above) gives details on the effects 
of cigarette smoke and e-cigarette aerosol on cultured primary lung 
vascular endothelial cells. Changes noted included nicotine-related 
loss of endothelial barrier function, inflammation and reduced cell 
proliferation. E-cigarette aerosol was found to contain acrolein, 
a compound found in cigarette smoke and previously reported to 
Copyright © 2015 by the International Association for the Study of Lung Cancer
1128 Copyright © 2015 by the International Association for the Study of Lung Cancer
•	 Tobacco, Trade, and the 
Machinations of Big Bully
dangers of smoking. The court found for the Ontario 
government and the case can therefore proceed to trial. 
The report from The Globe and Mail also notes that 
nine other provinces have filed similar lawsuits, yet 
to come to trial. A space worth watching. And in an 
indirect blow for Big Bully, in perhaps the most unlikely 
of places, Beijing has instituted a public smoking ban, 
as of Monday 1st of June. Smoke-free places include 
cafes, bars, restaurants, hotels, schools, railway stations 
and hospitals with fines for smokers of 200 yuan and 
for business owners of up to 10,000 yuan. Ashtrays 
have vanished and anti-smoking banners have gone 
up, including on the “birds-nest” national stadium, but 
there are doubts about its enforcement. Other Chinese 
cities including Shanghai have introduced bans but 
enforcement has been somewhat limited. However, 
government hotlines have started receiving complaints 
about smoking in public and anti-tobacco campaigners 
are embracing the bans.
http://www.reuters.com/article/2015/06/03/
wto-tobacco-idUSL5N0YP3S420150603
http://www.theglobeandmail.com/news/
national/ontario-wins-important-victory-in-
50-billion-lawsuit-against-tobacco-firms/
article12270561/
http://qz.com/420686/how-beijings-four-million-
smokers-are-barely-coping-with-a-new-smoking-ban/
http://www.theguardian.com/world/2015/jun/01/
beijing-bans-smoking-public-places
http://www.theglobeandmail.com/globe-debate/
can-you-imagine-a-smoke-free-china/article24457070/
Readers of this column may recall, about a year ago, mention of 
Ukraine as an opponent of Australia’s plain packaging legislation. 
How and Why you may ask? Because, as again you may recall, 
Ukraine (really on behalf of Big Tobacco, with admitted support 
from BAT), initiated a WTO dispute opposing the plain packaging 
legislation on the basis of unfair trade restriction on tobacco 
products. However, as reported by Reuters, Ukraine has suspended 
these proceedings, a suspension that lasts 12 months at the end of 
which Ukraine may lose the right to return to the panel proceedings. 
As noted in the report, Ukraine was an odd opponent to Australia’s 
legislation; not only did Ukraine not export tobacco to Australia, 
it is also a party to the FCTC and has backed guidelines on 
enforcement of the treaty, including plain packaging. In another 
blow for Big Bully, a Canadian lawsuit has won a preliminary 
round to obtain damages against tobacco manufacturers. Six 
tobacco companies argued in the Ontario Court of Appeal, that the 
court did not have jurisdiction for orders as a result of litigation. 
The lawsuit alleges that the companies marketed tobacco without 
concern for health and that they withheld information about the 
